7 completed, 7 terminated, 4 withdrawn, 2 active not recruiting. 20 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 7, Terminated 7, Withdrawn 4, Active not recruiting 2 |
| Phase 2 | 6 | Terminated 4, Completed 1, Withdrawn 1 |
Follow magrolimab: new trials by email Literature Review of magrolimab trials Research Report on magrolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants Sabatolimab, Magrolimab, Azacitidine - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2024-12-20 | 2024-04-11 | |
| Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2024-10-09 | 2024-09-19 | |
| Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2024-03-05 | 2024-05-02 | |
| Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma Magrolimab, Cisplatin, Gemcitabine - Advanced Urothelial Carcinoma | Phase 1 | Withdrawn | Insel Gruppe AG, University Hospital Bern | 2023-06-21 | 2024-07-05 | |
| Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Magrolimab - Brain Cancer, Malignant Brain Tumor | Phase 1 | Completed | University of California, San Francisco | 13 | 2022-04-22 | 2025-07-09 |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Obinutuzumab, Venetoclax, Magrolimab - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2021-12-16 | 2025-02-04 |
| The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer ONO-7913, ONO-4538, Fluorouracil - Unresectable Colorectal Cancer | Phase 1 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 65 | 2021-09-23 | 2026-10-07 |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2021-08-31 | 2026-06-30 |
| An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer ONO-7913, ONO-4538, Oxaliplatin - Metastatic Pancreatic Cancer | Phase 1 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 32 | 2021-07-30 | 2026-10-07 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2021-04-06 | 2025-10-16 |
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia Azacitidine, Magrolimab, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 110 | 2020-07-28 | 2026-04-23 |
| A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia Atezolizumab, Hu5F9-G4 - Acute Myeloid Leukemia | Phase 1 | Terminated | Hoffmann-La Roche | 13 | 2019-10-08 | 2022-02-21 |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) Atezolizumab, Enfortumab Vedotin, Niraparib - Urothelial Carcinoma, Bladder Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 272 | 2019-06-01 | 2026-08-03 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL | Phase 1 | Completed | Acerta Pharma BV | 30 | 2018-06-19 | 2022-08-15 |
| Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy Magrolimab, Avelumab - Ovarian Cancer | Phase 1 | Completed | Gilead Sciences | 34 | 2018-05-23 | 2024-04-01 |
| Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies Magrolimab, Azacitidine - Hematological Malignancies | Phase 1 | Terminated | Gilead Sciences | 258 | 2017-09-08 | 2025-01-17 |
| Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Magrolimab, Rituximab, Gemcitabine - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Gilead Sciences | 178 | 2016-11-21 | 2025-05-29 |
| Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer Magrolimab, Cetuximab - Solid Tumor, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Gilead Sciences | 78 | 2016-11-02 | 2021-03-01 |
| CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies Hu5F9-G4 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Gilead Sciences | 20 | 2015-11-01 | 2019-02-21 |
| Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody Hu5F9-G4 - Solid Tumor | Phase 1 | Completed | Gilead Sciences | 88 | 2014-08-01 | 2019-02-05 |
Leukemia, Myeloid, Acute (5) · Myelodysplastic Syndromes (3) · Lymphoma, Non-Hodgkin (2) · Brain Neoplasms (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Mycosis Fungoides (1) · Neuroblastoma (1) · Osteosarcoma (1)
Gilead Sciences (6) · National Cancer Institute (NCI) (4) · Hoffmann-La Roche (2) · Ono Pharmaceutical Co., Ltd. (2) · Acerta Pharma BV (1) · City of Hope Medical Center (1) · Insel Gruppe AG, University Hospital Bern (1) · M.D. Anderson Cancer Center (1) · Novartis Pharmaceuticals (1) · University of California, San Francisco (1)
United States (14) · United Kingdom (5) · Japan (2) · Australia (1) · Canada (1) · France (1) · Greece (1) · South Korea (1) · Spain (1) · Taiwan (1)
Project Leader (2) · Bernhard Kiss, Professor (1) · Chris Takimoto, MD (1) · Haider S Mahdi (1) · Howard Colman, MD PhD FAAN (1) · Ian Flinn, MD, PhD (1) · Mark Chao, MD PhD (1) · Mark J Roschewski, M.D. (1) · Michael S Khodadoust (1) · Monzr M Al Malki, MD (1) · Naval G Daver (1) · Nicholas Whipple, MD, MPH (1)
PMID 26390038, PMID 30811285, PMID 31183877, PMID 36888930, PMID 37651261, PMID 39213421, PMID 39293083, PMID 40318595
2017 (2), 2015 (1), 2016 (1), 2023 (1), P30CA015704 (1), P30CA033572 (1), U01CA154967 (1), UM1CA186690 (1), UM1CA186717 (1), UM1CA228823 (1)